Recently, following the C round of financing of more than 300 million yuan in 2023 and the strategic financing of tens of millions of yuan from Huaxia Ophthalmology, the global high-end optical ophthalmic diagnosis and treatment equipment brand Intalight - Vision Micro Imaging (Henan) Technology Co., Ltd. (hereinafter referred to as "Intalight" or "Vision Micro Imaging") has recently completed a Series D financing of over 100 million yuan led by Haitong Kaiyuan, and the financing will be mainly used to increase R&D investment, expand product lines and accelerate overseas market layout.
It is also understood that not long ago, VisionMicro Imaging initiated a trade secret infringement and patent ownership lawsuit against Beijing Tupai Medical Technology Co., Ltd. and Wu Heng (formerly VisionMicro Imaging Optical Engineer), and applied to the Shanghai Intellectual Property Court for property preservation, and according to the two property preservation notices, the court has sealed (froze) the preserved person Beijing Topai Medical Technology Co., Ltd. for a total of 10,400,000 yuan (one thousand thousand yuan). As a science and technology innovation enterprise based on hard-core technological innovation, the use of legal weapons to protect its own rights and interests is not only to protect its own independent research and development and innovation achievements, but also to create and maintain a good innovation atmosphere in China.
Based on a world-class R&D team with more than 20 years of engineering experience in Silicon Valley, Intalight has built a world-leading, software-hardware integrated technology and product competitiveness. Within one year, Intalight Saiwei completed multiple financings, with a total financing amount of more than 400 million, and its investors include China Life Equity, Qianhai Ark, Chende Capital, Shenzhen Venture Capital, CICC Huirong, Lingang Lanwan and other domestic first-line financial investment institutions, as well as investors in the two major ophthalmology industries of Aier Medical and Huaxia Ophthalmology. The investment of Haitong Kaiyuan will inject new impetus into the development of Intalight!
In the domestic market, the cumulative sales of Intalight Ruyi full-eye OCT have exceeded 300 units, and more than 100 units have been installed in national and provincial benchmark hospitals, and more than 80% of the equipment has become the main model, and has maintained a steady growth momentum. According to the statistics of public hospitals, the market share and overall winning price of OCT products are in a leading position among similar brands. In addition, Intalight has published more than 110 SCI papers in international journals in cooperation with experts and professors at home and abroad, becoming a "vanguard" enterprise of high-end ophthalmic equipment in China.
Based on its solid leading position, Intalight has accelerated its globalization. At present, it has set up a R&D center in Silicon Valley in the United States, a sales sub-center in France, and established a growing and mature overseas market team. At present, Ruyi Whole Eye OCT has been installed in 13 top ophthalmology centers in Europe and the United States, among which well-known hospitals and experts include: Professor Philip Rosenfeld's team at Bascom Palmer Eye Institute at the University of Miami, Professor David Huang and Professor Yali Jia's team at Casey Eye Institute, Oregon Health and University of Science and Technology, Professor Ricky Wang's team at the University of Washington, The team of Professor Robert Chang of Stanford University in the United States, the team of Adil EL Maftouhi, a French ophthalmic imaging expert, and the team of Professor Stefan Sacu of the Vienna General Hospital (AKH) of the Medical University of Vienna, etc. In addition, Ruyi Whole Eye OCT has also been installed in well-known ophthalmology institutions in the Asia-Pacific region such as Tan Tock Seng Hospital in Singapore and Natasha Eye Center in India, and will be stationed in more well-known hospitals in the near future.
It is worth mentioning that at the beginning of 2024, Intalight Ruyi's full-eye OCT strength was listed on the 2023 Top Retinal Imaging Solutions Provider 2023 released by Medtech Outlook, a world-renowned and authoritative medical technology magazine, and won this world award, representing the global ophthalmology academic community's DREAM OCT's high recognition once again demonstrates its extensive influence in overseas markets.
Over the years, Intalight has been continuously cultivating technology in the field of ophthalmology based on a high-level international team. Under the leadership of Dr. Peng Xianzhao, an expert in optical systems, and Dr. Li Bing, an expert in medical image algorithms, Intalight has assembled a multinational and cross-field world-class R&D team that integrates semiconductor engineers, science champions, and returnees from Silicon Valley. Based on this, Intalight has continuously launched new products and technologies that are at the forefront of the world, and has maintained a high innovation speed, constantly iterating and setting new standards in image quality, detection rate, breadth and other indicators.
In terms of ophthalmic OCT products, Intalight launched the world's first 200,000-speed commercial swept OCT in 2019, and was the first in the world to be equipped with artificial intelligence layering technology on a commercial aircraft. In 2020, the world's first 16.2mm super depth imaging product was launched, setting a new record for the maximum imaging depth of commercial OCT. In 2021, the world's first 130° ultra-wide-angle OCTA broke through the limit of the maximum single scanning range of commercial OCT and broadened the clinical indications. In 2022, the new product "Ruyi Whole Eye OCT" made its world premiere, which perfectly integrates the five cutting-edge functions of visual biomeasurement of the whole eye axis, anterior OCT, posterior OCT, anterior OCTA and posterior OCTA in one device, opening a new era of full-eye OCT. In 2023, the world's first 150° ultra-wide-angle OCTA product will be launched, pushing the level of OCT technology to a new level.
Intalight continues to expand the application boundaries of swept OCT, expanding from the fundus to the fields of refraction and optometry. In 2023, we will successively launch a revolutionary new technology of full-ocular scanning biomeasurement with an ocular axial detection rate of over 99% in cataract patients, and a fast fitting solution for scleral lenses based on swept OCT.
Fully exploiting the advantages of the international R&D team, Intalight has continuously entered the field of ophthalmic treatment equipment with higher technical requirements on the basis of ophthalmic diagnostic equipment, and has continuously made new breakthroughs in its ultra-wide-angle true color fundus camera and full femtosecond refractive surgery system project with new optical design. Determined to become the world's leading ophthalmic device brand, Intalight will join hands with global ophthalmology experts to launch more world-class technical products, provide more advanced technologies and solutions for global ophthalmology doctors and patients, and light up more light!